Pharmacist interviews test your knowledge of pharmacology and pharmaceutics, drug interactions, Indian drug regulations, quality standards and how you counsel patients. These questions suit D.Pharm, B.Pharm and Pharm.D graduates applying for hospital, retail, industry and regulatory roles.
These answers are for interview preparation and follow standard teaching. They are not clinical guidance; always follow current protocols and your institution's policies.
Fundamentals, definitions and simple scenarios. Good for freshers and warm-ups.
Pharmacokinetics is what the body does to the drug: absorption, distribution, metabolism and excretion (ADME). It decides how much drug reaches the site of action and for how long. Pharmacodynamics is what the drug does to the body: its mechanism of action, receptor binding, the dose-response relationship and its effects and side effects.
Bioavailability is the fraction of an administered dose that reaches the systemic circulation unchanged. An intravenous dose has 100% bioavailability by definition. Oral bioavailability is often lower because of incomplete absorption and first-pass metabolism in the gut wall and liver. That is why some drugs, such as nitroglycerin, are given sublingually, and why oral and IV doses of the same drug can differ.
A generic drug contains the same active ingredient, in the same strength, dosage form and route, as the original branded drug, and must be shown to be bioequivalent, meaning it delivers the drug into the blood at a comparable rate and extent. Inactive ingredients, appearance and price can differ; generics are usually much cheaper because they do not carry the original research and marketing costs.
These schedules come under the Drugs and Cosmetics Rules, 1945. Schedule H drugs can be sold only against the prescription of a registered medical practitioner. Schedule H1 covers certain antibiotics, anti-TB drugs and habit-forming drugs, and the pharmacist must keep a separate register of the prescriber, patient, drug and quantity. Schedule X covers narcotic and psychotropic drugs with stricter storage, prescription and record-keeping requirements.
Applied problems, trade-offs and questions about your own projects.
Pharmacokinetic interactions change drug levels: fluconazole inhibits the enzyme that breaks down warfarin and raises the INR and bleeding risk, and rifampicin induces liver enzymes and can make oral contraceptives fail. Pharmacodynamic interactions change the effect: combining two drugs that prolong the QT interval raises the risk of arrhythmia. Food can interact too: grapefruit juice raises levels of some statins by inhibiting CYP3A4.
Half-life is the time for the drug's plasma concentration to fall by half. With regular dosing, a drug reaches steady state, where the amount going in equals the amount eliminated, after about four to five half-lives. Half-life guides how often a drug is given. When a quick effect is needed for a drug with a long half-life, a loading dose is used to reach target levels sooner.
Good Manufacturing Practice is a quality system that ensures medicines are consistently produced and controlled to the right standards. It covers qualified staff and training, clean and controlled premises, qualified equipment, validated processes, complete documentation and batch records, quality control testing, and handling of deviations, complaints and recalls with corrective and preventive actions. In India, GMP requirements are in Schedule M of the Drugs and Cosmetics Rules.
An enteric coating does not dissolve in the acidic stomach but dissolves in the more alkaline small intestine. It is used to protect drugs that stomach acid would destroy, such as some proton pump inhibitors like omeprazole, and to protect the stomach from irritating drugs, such as aspirin. Patients should not crush or chew enteric-coated tablets, because that defeats the coating.
System design, deep internals, leadership and tough follow-ups.
Pharmacovigilance is the science of detecting, assessing, understanding and preventing adverse effects and other drug-related problems. In India it is run through the Pharmacovigilance Programme of India (PvPI), coordinated by the Indian Pharmacopoeia Commission, where healthcare professionals and patients report suspected adverse drug reactions. Reports are assessed for causality, using scales such as WHO-UMC or Naranjo, and can lead to label changes, warnings or withdrawal of a drug.
I explain why they are taking it and to take it at the same time every day. I stress regular INR blood tests and keeping to the dose the doctor sets. I list the signs of bleeding to report: unusual bruising, blood in the urine or stools, black stools, severe headache. I advise keeping their vitamin K intake (green leafy vegetables) consistent rather than avoiding it, avoiding painkillers like ibuprofen and aspirin unless prescribed, checking before starting any new medicine or herbal product, and telling every doctor and dentist they take warfarin.
Phase I tests safety, tolerability and dosing in a small group, often healthy volunteers. Phase II tests efficacy and side effects in a few hundred patients. Phase III confirms efficacy and safety in large numbers of patients, usually against standard treatment, and supports approval. Phase IV is post-marketing surveillance after approval. In India, clinical trials are regulated by CDSCO under the New Drugs and Clinical Trials Rules, 2019, with ethics committee approval and informed consent.
I do not dispense it as written, and I do not change it myself. I check references to confirm the concern, such as a dose far above the usual range, a dangerous interaction or a known allergy, then contact the prescriber politely and professionally to clarify. I document the conversation and any change, and explain to the patient that I am confirming the prescription to ensure their safety.